Clinical trial NCT02890160: A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-II
Official title: A Randomized Trial of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease: FUTURE-II
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Coronary Artery Disease
Keywords: Bioresorbable Vascular Scaffold
Lead sponsor: Shanghai MicroPort Medical (Group) Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2016-09-07
Enrollment: 430
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The FUTURE-II study is a confirmative clinical trial for Sirolimus Target Eluting Bioresorbable Vascular Scaffold (Firesorb) after the feasibility and safety of the device has been preliminary confirmed in a small-scale First-in-Man clinical trial.

Detailed description: This study is a prospective, multicenter, single-blind, randomized controlled trial in patients with coronary artery disease caused by up to two de novo native coronary artery lesions in separate epicardial vessels. The goal is to evaluate the safety and effectiveness of Firesorb to support the approval of the Chinese Food and Drug Administration (CFDA) for this product. The Abbott's XIENCE Everolimus-eluting Coronary Stent System is selected as the control device. 430 subjects will be recruited. All subjects will be 1:1 randomly assigned to experimental group and control group. All subjects will undergo clinical follow-up at 1-month, 6-month, 1-year, 2-year, 3-year, 4-year and 5-year post-index procedure. All subjects will undergo angiographic follow-up at 1-year post-index procedure; of which 3-5 centers will be specified as a subgroup to complete OCT follow-up (n=80, 40 each in test and control group).

Eligibility criteria: General Inclusion Criteria:

1. 18-75 years of age, males or non-pregnant females;
2. With silent ischemia evidence, patients with stable or unstable angina, or in patients with old myocardial infarction;
3. Patients with indications for coronary artery bypass graft surgery;
4. To understand the purpose of testing, voluntary and informed consent, patients undergoing invasive imaging follow-up.

Angiographic Inclusion Criteria:

1. One or two de novo target lesions:

   1. If there is one target lesion, a second non-target lesion may be treated but the non-target lesion must be present in a different epicardial vessel, and must be treated first with a successful, uncomplicated result prior to randomization of the target lesion.
   2. If two target lesions are present, they must be present in different epicardial vessels and both must satisfy the angiographic eligibility criteria.
   3. The definition of epicardial vessels means the LAD, LCX and RCA and their branches. Thus, the patient must not have lesions requiring treatment in e.g. both the LAD and a diagonal branch.
2. Target lesion(s) must be located in a native coronary artery with a visually estimated or quantitatively assessed % diameter stenosis (DS) of ≥ 50% and \< 100% with a thrombolysis in myocardial infarction (TIMI) flow of ≥1 and one of the following: stenosis ≥ 70%, an abnormal functional test (e.g. fractional flow reserve, stress test), unstable angina or post-infarct angina. Lesion(s) must be located in a native coronary artery with RVD by visual estimation of ≥ 2.5 mm and ≤4.0 mm. Lesion(s) must be located in a native coronary artery with length by visual estimation of ≤ 25 mm.
3. Each target lesion may be covered with one stent.

General Exclusion Criteria:

1. Within 1 week of any acute myocardial infarction or myocardial enzymes did not return to normal;
2. Implantation of stent in target vessel within 1 year , patients with planned intervention again within six months;
3. Severe congestive heart failure (NYHA III and above) ,or left ventricular ejection fraction \<40% (ultrasound or left ventricular angiography);
4. Preoperative renal function serum creatinine \>2.0mg/DL; receiving hemodialysis;
5. Bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage and half year history of ischemic stroke, antiplatelet agents and would not allow an anticoagulant therapy contraindications patients undergoing antithrombotic therapy;
6. Aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer and rapamycin allergies;
7. The patient's life expectancy is less than 12 months;
8. Top participated in other drug or medical device and does not meet the primary study endpoint in clinical trials time frame;
9. Researchers determine patient compliance is poor, unable to complete the study in accordance with the requirements;
10. Heart transplantation patients;
11. The unstable arrhythmia, such as high risk ventricular extrasystole and ventricular tachycardia;
12. Cancer need chemotherapy;
13. Immunosuppression and autoimmune diseases, planned or undergoing immunosuppressive therapy;
14. Planning or being receiving long-term anticoagulant therapy, such as heparin, warfarin, etc;
15. Within six months for elective surgery requires stopping aspirin, Clopidogrel patients;
16. Blood test prompted platelet counts of less than 100x10E9/L or greater than 700x10E9/L, white blood cells than 3x10E9/L; known or suspected liver disease (such as hepatitis);
17. Peripheral vascular disease, 6F catheter is not available.

Angiographic Exclusion Criteria:

1. left main coronary artery disease;
2. severe triple vessel lesion and required revascularization.

The following exclusion criteria apply to the target lesion(s) or target vessel(s):

1. Aorto-ostial right coronary artery (RCA) lesion (within 3 mm of the ostium).
2. Lesion located within 3 mm of the origin of the Left Anterior Descending Artery (LAD) or left circumflex artery (LCX).
3. Lesion involving a bifurcation with a:

   1. side branch ≥ 2.5 mm in diameter, or
   2. side branch with diameter stenosis ≥ 50%, or
   3. side branch requiring guide wire, or
   4. side branch requiring dilatation.
4. Anatomy proximal to or within the lesion that may impair delivery of Firesorb or XIENCE stent:

   1. Extreme angulation (≥ 90°) proximal to or within the target lesion.
   2. Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion.
   3. Moderate or heavy calcification proximal to or within the target lesion.
5. Lesion or vessel involves a myocardial bridge.
6. Vessel contains thrombus as indicated in the angiographic images or by IVUS or OCT.
7. Vessel has been previously treated with a stent at any time prior to the index procedure such that the Firesorb or XIENCE would need to cross the stent to reach the target lesion.
8. Vessel has been previously treated and the target lesion is within 5 mm proximal or distal to a previously treated lesion.
9. Lesion which prevents successful balloon pre-dilatation, defined as full balloon expansion with the following outcomes:

   1. Residual %DS is a maximum of \< 40% (per visual estimation), ≤ 20% is strongly recommended.
   2. TIMI Grade-3 flow (per visual estimation).
   3. No angiographic complications (e.g. distal embolization, side branch closure).
   4. No dissections National Heart Lung and Blood Institute (NHLBI) grade D-F.
   5. No chest pain lasting \> 5 minutes.
   6. No ST depression or elevation lasting \> 5 minutes.

Primary outcomes:
measure: In-segment Late Lumen Loss (LLL) (Queue 1)
timeFrame: 1 year after index procedure
Secondary outcomes:
measure: The percentage of intima coverage-strut (OCT subgroup)
timeFrame: 1 year after index procedure
measure: Vasomotion (Queue 2)
timeFrame: 2 year after index procedure
measure: Acute Success-Device Success
timeFrame: From the start of index procedure to end of index procedure
measure: Acute Success-Procedural Success
timeFrame: At time of procedure up to 7 days in hospital
measure: Device-oriented composite endpoints (Target Lesion Failure)
timeFrame: 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
measure: Patient-oriented clinical composite endpoint (PoCE)
timeFrame: 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
measure: Death (Cardiac, Vascular, Non-cardiovascular)
timeFrame: 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
measure: Myocardial Infarction (MI)
timeFrame: 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
measure: Target Vessel Revascularization (TVR)
timeFrame: 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
measure: Target Lesion Revascularization (TLR)
timeFrame: 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
measure: Any Revascularization
timeFrame: 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
measure: Scaffold/Stent Thrombosis (per ARC definition)
timeFrame: 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
measure: Site Diagnosed Angina (SDA)
timeFrame: 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
measure: Minimum Lumen Diameter (MLD)
timeFrame: 1 year and 2 years after index procedure
measure: percentage of diameter stenosis (%DS)
timeFrame: 1 year and 2 years after index procedure
measure: Angiographic Binary Restenosis (ABR)
timeFrame: 1 year and 2 years after index procedure
measure: Late Lumen Loss (LLL)
timeFrame: 1 year and 2 years after index procedure
measure: Acute Stent Recoil
timeFrame: Immediately after index procedure
measure: Descriptive analysis of morphometric, lesion composition and scaffold strut data obtained with OCT
timeFrame: 1 year and 2 years after index procedure
Other outcomes:
Locations:
city: Peking
country: China
facility: Fu Wai Hospital
state: Beijing
Study officials:
affiliation: Fu Wai Hospital & National Center for Cardiovascular Diseases in China
name: Runlin Gao, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Song L, Xu B, Chen Y, Zhou Y, Jia S, Zhong Z, Su X, Ma Y, Zhang Q, Liu J, Wang Y, Guan C, Zheng M, Qiao S, Gao R; FUTURE-II Trial Investigators. Thinner Strut Sirolimus-Eluting BRS Versus EES in Patients With Coronary Artery Disease: FUTURE-II Trial. JACC Cardiovasc Interv. 2021 Jul 12;14(13):1450-1462. doi: 10.1016/j.jcin.2021.04.048. Epub 2021 May 18.